<?xml version="1.0" encoding="UTF-8"?>
<p id="p0105">The anti-depressant drug lithium is a well-known Food and Drug Administration-approved drug for nearly 60 years. Accumulating evidence suggests that LiCl have diversity of functions on physiological and pathological processes, including cancerogenic or anti-cancerogenic properties, immune-stimulatory and immunosuppressive functions [
 <xref rid="bib6" ref-type="bibr">6</xref>,
 <xref rid="bib7" ref-type="bibr">7</xref>]. There are several studies exploring the roles of LiCl on virus infection and suggesting that LiCl inhibit certain virus replication, such as transmissible gastroenteritis coronavirus, HIV, canine parvovirus, PRRSV and so on [
 <xref rid="bib8" ref-type="bibr">[8]</xref>, 
 <xref rid="bib9" ref-type="bibr">[9]</xref>, 
 <xref rid="bib10" ref-type="bibr">[10]</xref>, 
 <xref rid="bib11" ref-type="bibr">[11]</xref>, 
 <xref rid="bib12" ref-type="bibr">[12]</xref>, 
 <xref rid="bib13" ref-type="bibr">[13]</xref>, 
 <xref rid="bib14" ref-type="bibr">[14]</xref>, 
 <xref rid="bib15" ref-type="bibr">[15]</xref>]. In this study, we demonstrate that LiCl can also restrict CVB3 infection 
 <italic>in vivo</italic> and 
 <italic>in vitro</italic>.
</p>
